New Hepatitis C Treatment

Published Online: Friday, February 24, 2012
Follow Pharmacy_Times:
The standard treatment for hepatitis C, interferon and ribavirin, cures just 45% of those who receive it. There are now several dozen new drugs for the disease under development, and 2 were approved by the FDA in 2011: telaprevir and boceprevir. The new drugs, which directly attack the virus that causes hepatitis C with minimal impact on the human host, have raised hopes of shorter treatment times and higher cure rates. Researchers are also looking at ways of tailoring treatment to individual patients based on genetic testing.
 
To learn more, check out this video:

Related Articles
Interferon-free, all-oral drug regimens result in high rates of sustained virologic response for patients co-infected with hepatitis C virus and HIV.
This continuing education activity is supported by educational grants from Bristol-Myers Squibb and Gilead Sciences, Inc.
A recent study has identified how chronic hepatitis infection can pave the way to liver cancer.
AbbVie and Gilead are fighting over hepatitis C drug market share.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$